A Royal College of Physicians report found that brain tumour patients at University Hospitals Coventry and Warwickshire NHS trust were severely harmed by years of unnecessary chemotherapy. The review examined 20 patients and concluded that some had been kept on temozolomide for far longer than usual.
It found 15 cases of unsatisfactory care and five that required improvement. The report also said all living patients treated with more than 12 cycles of TMZ should have their cases independently reviewed.
Becky Jones and prolonged treatment
Becky Jones received more than 100 cycles of chemotherapy over a 10-year period after being incorrectly diagnosed with a grade-4 glioblastoma and told she had between six and 12 months to live. She said, “For years, I questioned why I was still being given chemotherapy when my scans were stable, but I was repeatedly told that without it I would die.”
Jones also said the report was “validating” and “incredibly painful,” and added, “I now need a full and honest explanation of what happened to me.” Her case sits at the centre of the report’s concern that some patients were left on treatment even after their cancer was progressing and there was no evidence continuing temozolomide would help.
Prof Andy Hardy and Sue Noyes
Prof Andy Hardy and Sue Noyes said they were “deeply sorry to all the patients and families affected by failures within our neuro-oncology service under the care of retired clinical oncologist Ian Brown.” Hardy also said, “We recognise the concern, distress and loss of trust experienced by those who placed their faith in us during some of the most difficult moments of their lives.”
He added, “While an apology alone cannot undo the issues experienced, we are clear that meaningful action is being taken.” Hardy also said, “These findings make for extremely difficult reading and raise serious questions about individual clinical decisions and historical governance.”
University Hospitals Coventry and Warwickshire NHS trust
The report focused on patients treated under Ian Brown, who retired in 2023 after concerns were raised by colleagues. It said some patients had been told they would die if they stopped chemotherapy, while others suffered significant toxicity, including fatigue, nausea, severe shingles requiring hospital admission, and nausea and vomiting.
One patient had more than 10 years of chemotherapy and was later found to have a grade-1 pilocytic astrocytoma. Another had a decade of treatment and experienced significant toxicity. More than 40 patients are being represented by Brabners, and the trust has said it is taking meaningful action after the findings were published.
The immediate next step is an independent review of living patients who received more than 12 cycles of TMZ. The report leaves one pressing gap: how many other patients treated under Ian Brown still need that review, and what their final diagnoses were.







